Core Viewpoint - Lisata Therapeutics, Inc. has entered into a binding term sheet for acquisition by Kuva Labs, Inc., with a cash offer of $4.00 per share, representing an approximate 85% premium over Lisata's recent closing stock price [1][2] Group 1: Acquisition Details - Kuva will commence a tender offer to purchase all outstanding shares of Lisata at $4.00 per share in cash [1] - Stockholders will receive two contingent value rights (CVRs) valued at $1 each, contingent upon specific milestones related to the drug certepetide [1][2] - The acquisition has been unanimously approved by the boards of directors of both companies, with a definitive purchase agreement expected before February 27, 2026 [1] Group 2: Product Information - Certepetide is an investigational drug designed to enhance the delivery of anti-cancer therapies to solid tumors, showing favorable safety and clinical activity in trials for pancreatic cancer [4][5] - The drug has received multiple designations, including Fast Track and Orphan Drug Designation for various cancers, indicating its potential in treating serious diseases [4][5] Group 3: Company Background - Lisata Therapeutics focuses on developing innovative therapies for advanced solid tumors and has established partnerships based on its CendR Platform technology [5] - Kuva Labs is a preclinical bioscience company developing the NanoMark direct MR imaging platform, aimed at improving cancer detection and treatment [7]

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Posting Hearing Information Pack, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Posting Hearing Information Pack. (the "Company") (A joint stock company incorporated in the People's Republic of China with limited liabili ...

Financial Data and Key Metrics Changes - For Q3 2025, operating expenses totaled $4.4 million, a decrease of $0.9 million or 17.3% compared to $5.3 million in Q3 2024 [6] - Research and development expenses were approximately $2 million, down from $2.5 million in Q3 2024, representing a decrease of $0.6 million or 22.9% [7] - General and administrative expenses were approximately $2.5 million, compared to $2.8 million in Q3 2024, a decrease of $0.3 million or 12.1% [8] - Net losses for Q3 2025 were $4.2 million, compared to $4.9 million in Q3 2024 [8] - As of September 30, 2025, cash and cash equivalents were approximately $19 million, projected to support operations into Q1 2027 [9] Business Line Data and Key Metrics Changes - The company achieved several development milestones for sirtepotide, including positive preliminary results from multiple studies [4] - A strategic alliance was formed with GATC Health to utilize their AI Drug Discovery Platform for identifying product candidates [5] Market Data and Key Metrics Changes - The ASCEND trial, a phase 2b study, is evaluating sirtepotide in combination with standard chemotherapy for metastatic pancreatic cancer, with preliminary data showing a positive trend in overall survival [11][13] - The Bolster trial, a phase 2a study, completed enrollment ahead of schedule, with top-line data expected in Q4 2025 [16] - The Sendafox trial, a phase 1b/2a study, showed promising early survival data, including a 60% two-year overall survival rate in pancreatic cancer patients [18] Company Strategy and Development Direction - The company is focused on expanding its development pipeline for sirtepotide across various cancer types and exploring non-oncology applications [24] - A new patent for sirtepotide was issued, extending protection until March 2040, covering its chemical structures and applications [25] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenging macro environment affecting small-cap biotech companies, impacting stock performance despite positive clinical results [28] - The company is actively seeking partnerships to fund future phase 3 trials, emphasizing the need for collaboration to minimize shareholder dilution [35] Other Important Information - The company has secured multiple special designations from the U.S. FDA and EMA for sirtepotide [10] - The iLISTA trial, evaluating sirtepotide in combination with immunotherapy, has completed enrollment, with final data expected in Q1 2026 [21][22] Q&A Session Summary Question: When should we expect the next phase 2b data cut for Sendafox? - The timeline is under the control of the investigator, and a precise estimate cannot be provided [26] Question: Can you provide an update on the GBM trial enrollment status? - Enrollment is approximately two-thirds complete, targeting 30 patients [27] Question: What does the cash flow runway to Q1 2027 include? - It covers all operating expenses and costs to support ongoing clinical trials, but does not include assumptions for a phase 3 trial for Sendafox [27] Question: Why has the stock not reacted positively to recent clinical data? - The company attributes this to a combination of negative market forces affecting small-cap biotech and limited trading activity among shareholders [28] Question: Is there a plan to pursue additional licensing opportunities? - The company is actively pursuing new licensing opportunities internally, leveraging existing partnerships [30] Question: What are the next steps following the final analysis of the Sendafox data? - The company plans to seek partners to help fund the phase 3 trial, as raising capital independently would be challenging in the current environment [34]

Core Insights - Lisata Therapeutics reported positive data from multiple clinical studies involving certepetide, highlighting its potential effectiveness in treating advanced solid tumors [3][4][6] - The company has formed a strategic alliance with GATC Health to utilize their AI-driven drug discovery platform, enhancing the development of certepetide and its applications [3][15] - Lisata has extended its cash runway into the first quarter of 2027, with no debt, indicating a stable financial position for ongoing operations [3][12] Business Developments - A global license agreement was established with Catalent for the use of certepetide in their SMARTag® Antibody-Drug Conjugate Technology Platform, which may enhance the targeting and effectiveness of ADCs [3][15] - The company achieved complete enrollment in the BOLSTER trial for cholangiocarcinoma ahead of schedule, with topline data expected in the fourth quarter of 2025 [8] - Certepetide has received multiple designations, including Fast Track and Orphan Drug Designation for various cancers, indicating its potential significance in oncology [5] Clinical Trial Highlights - The ASCEND trial showed promising preliminary results, with a positive trend in overall survival for patients treated with certepetide in combination with standard chemotherapy [4][6] - The CENDIFOX trial demonstrated a 50% R0 resection rate and a 70% pathologic partial response in patients with pancreatic cancer, suggesting that certepetide may enhance the effectiveness of existing therapies [8][10] - The iLSTA trial provided compelling data supporting certepetide's ability to improve immunotherapy outcomes in patients with locally advanced non-resectable pancreatic cancer [8][10] Financial Performance - For Q3 2025, operating expenses decreased to $4.4 million from $5.3 million in Q3 2024, reflecting a 17.3% reduction [9][11] - Research and development expenses were approximately $2.0 million, down 22.9% from the previous year, primarily due to lower spending in certain areas [10] - The company reported a net loss of $4.2 million for Q3 2025, compared to $4.9 million in Q3 2024, indicating improved financial management [11][19]

Core Insights - Arbutus Biopharma Corporation reported a strong second quarter in 2025, with total revenue of $10.7 million, significantly up from $1.7 million in the same period in 2024, primarily due to the recognition of previously-deferred revenue following the conclusion of its partnership with Qilu Pharmaceutical [8][11] - The company has strengthened its leadership team by appointing Dr. Roger Sawhney to the Board of Directors and Dr. Harry Janssen to the Scientific Advisory Board, enhancing its expertise in chronic hepatitis B virus (cHBV) programs [2][6] - Arbutus maintains a solid financial position with cash, cash equivalents, and marketable securities totaling $98.1 million as of June 30, 2025, although this is a decrease from $122.6 million at the end of 2024 [7][15] Financial Performance - Total revenue for Q2 2025 was $10.7 million, a $9.0 million increase compared to Q2 2024, attributed to the conclusion of the partnership with Qilu and the recognition of deferred revenue [8][11] - Research and development expenses decreased to $5.5 million in Q2 2025 from $15.6 million in Q2 2024, reflecting cost-saving measures implemented by the company [9] - General and administrative expenses also saw a reduction, falling to $3.3 million in Q2 2025 from $7.5 million in Q2 2024, due to cost-cutting efforts [10] Corporate Developments - The company concluded its strategic partnership with Qilu Pharmaceutical for the development and commercialization of imdusiran in Greater China, regaining global rights for the compound [5][6] - Dr. Harry Janssen's appointment to the Scientific Advisory Board is expected to enhance the company's clinical development efforts in cHBV [2][6] - Anuj Hasija resigned from the Board of Directors to focus on a new role at Vertex Pharmaceuticals, and Dr. Roger Sawhney has been appointed to fill the vacancy [2][6] Legal and Intellectual Property - Arbutus is actively involved in litigation to protect its intellectual property related to its patented LNP technology, with ongoing lawsuits against Moderna and Pfizer/BioNTech [5] - The summary judgment phase of the litigation against Moderna began in July 2025, with a jury trial scheduled for March 2026 [5]

Core Insights - Arbutus Biopharma Corporation has reacquired the rights to its lead compound, imdusiran, from Qilu Pharmaceutical, concluding their strategic partnership for the development and commercialization of imdusiran in Greater China [1][2] - The decision to terminate the partnership was influenced by Qilu's pipeline reprioritization and Arbutus' focus on advancing its pipeline efficiently [2] - Imdusiran has shown promising results, achieving functional cure in eight patients during Phase 2a trials [2][3] Company Overview - Arbutus Biopharma is a clinical-stage biopharmaceutical company focused on infectious diseases, particularly chronic hepatitis B virus (cHBV) [7] - The company is also developing an oral PD-1 inhibitor (AB-101) for cHBV treatment and is involved in legal actions to protect its intellectual property related to its patented LNP technology [7] Product Details - Imdusiran is designed to reduce all HBV viral proteins and antigens, which is essential for reawakening the immune system to control the virus [5] - The treatment has been reported to be generally safe and well-tolerated, with significant reductions in hepatitis B surface antigen (HBsAg) and HBV DNA [5] Scientific Advisory Board - Arbutus has established a new Scientific Advisory Board consisting of experts in chronic hepatitis B treatment to guide its strategic evaluation of the cHBV pipeline [2]

Core Insights - Lisata Therapeutics is making significant progress in its clinical development portfolio, particularly with the drug certepetide, despite challenges in the small-cap healthcare market [2][3] - The company has extended its cash runway into the third quarter of 2026, maintaining a strong financial position with no debt [1][11] Clinical Development Highlights - Certepetide is being evaluated in multiple clinical trials for solid tumors, showing promising results in Cohort A of the ASCEND trial, with a positive trend in overall survival [3][4] - Cohort B results from the ASCEND trial are anticipated soon, with preliminary data accepted for presentation at the ESMO Gastrointestinal Cancers Congress [4] - The BOLSTER trial for cholangiocarcinoma has completed enrollment ahead of schedule, with topline data expected in mid-2025 [4] - The CENDIFOX trial has completed enrollment, providing valuable data for immune profiling and long-term patient outcomes [4] - The iLSTA trial is on track for completion, with preliminary results indicating that certepetide enhances immunotherapy effectiveness [4] Financial Performance - For Q1 2025, operating expenses decreased to $5.8 million from $6.6 million in Q1 2024, a reduction of 11.4% [7] - Research and development expenses were approximately $2.6 million, down 19.7% from $3.2 million in the same period last year [8] - General and administrative expenses slightly decreased to $3.2 million from $3.4 million year-over-year [9] - The net loss for Q1 2025 was $4.7 million, compared to $5.4 million in Q1 2024 [10] Balance Sheet Overview - As of March 31, 2025, the company had cash, cash equivalents, and marketable securities totaling approximately $25.8 million [11] - Total liabilities were reported at $3.9 million, with total equity at $25.1 million [19]